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ABSTRACT
It is well established that transcription and alterna-
tive splicing events are functionally coupled during
gene expression. Here, we report that protein
arginine N-methyltransferase 6 (PRMT6) may play a
key role in this coupling process by functioning as a
transcriptional coactivator that can also regulate
alternative splicing. PRMT6 coactivates the
progesterone, glucocorticoid and oestrogen recep-
tors in luciferase reporter assays in a hormone-
dependent manner. In addition, small interfering
RNA (siRNA) oligonucleotide duplex knockdown of
PRMT6 disrupts oestrogen-stimulated transcription
of endogenous GREB1 and progesterone receptor
in MCF-7 breast cancer cells, demonstrating the
importance of PRMT6 in hormone-dependent tran-
scription. In contrast, the regulation of alternative
splicing by PRMT6 is hormone independent. siRNA
knockdown of PRMT6 increases the exon inclu-
sion:skipping ratio of alternatively spliced exons in
endogenous vascular endothelial growth factor and
spleen tyrosine kinase RNA transcripts in both the
presence and absence of oestrogen. These results
demonstrate that PRMT6 has a dual role in
regulating gene expression and that these two func-
tions can occur independently of each other.
INTRODUCTION
Steroid hormone receptors (SHRs) and nuclear receptors
(NRs) are members of a large superfamily of
ligand-inducible transcription factors (1,2). SHRs/NRs
activate transcription in a ligand-dependent manner by
binding to hormone response elements in promoters and
enhancer regions of target genes. DNA-bound SHRs/NRs
recruit coactivators, which are often recruited to gene pro-
moters in multi-protein complexes where they help to
reorganize chromatin into a transcriptionally active state
by remodelling nucleosomes or modifying histone tails
(3,4). The p160/steroid receptor coactivator (SRC)
family of SHR/NR coactivators is comprised of three
related proteins: SRC-1, SRC-2/GRIP1/TIF2 and
SRC-3/pCIP/ACTR/AIB1/RAC3/TRAM1. The p160/
SRC coactivators bind directly to the carboxyl terminal
activation function-2 domain of SHRs/NRs via three NR
boxes, each consisting of an LXXLL motif (where L is a
leucine and X is any amino acid), and recruit secondary
coactivators via their activation domains (ADs) (5). The
basic-helix–loop–helix/Per-Arnt-Sim (bHLH/PAS)
domain of p160/SRC proteins binds to the secondary
coactivators CoCoA, GAC63, hMMS19 and Fli-I (6–9);
the AD1 binds to the acetyltransferases CREB-binding
protein (CBP) and p300 (10,11); and the AD2 recruits
the protein N-arginine methyltransferases (PRMTs)
PRMT1 and coactivator associated arginine
methyltransferase 1 (CARM1/PRMT4) (12,13).
PRMT1 and CARM1 both function as secondary
coactivators for the oestrogen receptor-a (ERa), thyroid
hormone receptor (TR) and androgen receptor (AR)
(12,13). They require their enzymatic activity for this
process, which results in the transfer of either one or
two methyl groups from the methyl donor S-adenosyl-L-
methionine to guanidino nitrogen atoms in arginine
residues. (14,15). Methylation of arginine residues on
histone tails is believed to play a major role in
transcriptional activation by PRMTs (16–18). In
addition, PRMTs have been demonstrated to methylate
an increasing number of non-histone proteins involved
in transcription (19,20). For example, methylation of
various sites of CBP, p300 and RAC3 by CARM1 regu-
lates the ability of these proteins to bind to other
coactivators, and thus may play a role in controlling the
assembly and disassembly of coactivator complexes on an
active promoter (21–23). This regulation of coactivator
complex formation means that CARM1 activity
enhances the ability of other coactivators to promote tran-
scription. Indeed, CARM1 acts synergistically with
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or any of the three acetyltransferases p300, CBP or p/CAF
to stimulate steroid hormone-dependent transcription
(6,8,9,13,24–28). This demonstrates that PRMTs are an
integral component of the steroid-hormone-signalling
pathway and are required to fully activate steroid-
hormone-regulated genes.
Transcriptional coactivators, including CoAA, p72,
CAPERa and CAPERb, Sam68, p68, ASC-1, ASC-2
and CARM1, have been found to also regulate pre-
mRNA processing (29–34). Indeed, over 20 transcri-
ptional coregulators are structurally or functionally
related to known splicing factors (35). CARM1 is the
only PRMT previously shown to directly regulate alterna-
tive splicing. CARM1 methylates the splicing factors
CA150, SAP49, SmB and U1C and promotes skipping
of both a splicing reporter and the endogenous CD44
gene in a methylation-dependent manner (31). The exact
mechanism behind splicing regulation by CARM1 is
unknown. However, arginine methylation can promote
the assembly of small nuclear ribonucleoproteins
(snRNPs), and regulate the localization of many RNA-
binding proteins, such as heterogeneous nuclear ribo-
nucleoproteins (hnRNPs) (36–39).
Protein arginine N-methyltransferase 6 (PRMT6) is a
predominantly nuclear, type-I arginine methyltransferase,
that has been demonstrated to methylate Histone 3
on arginine 2 (H3R2), H4R3 and H2AR3 (40–42).
PRMT6 has also been found to methylate the HIV Tat,
nucleocapsid and Rev proteins, which interferes with the
ability of these proteins to interact with RNA (43–45).
PRMT6 can also methylate the splicing factors RDA288
and hnRNP D (31). As PRMT6 targets are involved in
both transcription and RNA processing, we investigated
the ability of PRMT6 to regulate these events. Here, we
report that PRMT6 coactivates SHR-dependent transcrip-
tion in a hormone-dependent manner, and regulates alter-
native splicing by means of a hormone-independent
mechanism.
MATERIALS AND METHODS
Plasmids
The pCDNA3.1-PR, pCDNA3.1-ERa, pCDNA3.1-ERb,
pCMX-b-galactosidase, pCMX-VP16-N, pCMX-
GAL4-N, pG5E1b-luciferase, pGL3-E1b-luciferase,
pGL3-PRE-E1b-luciferase, pGL3-ERE-E1b-luciferase,
pSG5 (Stratagene), pCMX and pCM5 expression and
reporter plasmids have all been described previously
(29,30,46). The RARE-E1b-luciferase was constructed by
inserting the sequence 50-GTACCGGGTAGGGTTCAC
CGAAAGT TCACTCGACGGGTAGGGTTCACCGA
AAGTTCACTCGAG-30 containing two retinoic acid
receptor (RAR) response elements and its corresponding
complementary sequence into the Asp718/Nhe1 sites of
pGL3-E1b-luciferase. The human SRC-1 complementary
DNA (cDNA) was a gift from Dr William W. Chin and
was cloned into a pCMX, pCMX-GAL4-N or
pSG5-based expression vectors. The pSV-GR and
pCMX-RARa plasmids were gifts from Dr David D.
Moore. The pSG5-HA-CARM1 was a gift from Dr
Michael R. Stallcup (12). The peroxisome proliferator
activated receptor-g (PPARg) and the PPAR-TK-
luciferase vectors were a gift from Dr Jon Whitehead.
The cDNAs for human PRMT6 and human PRMT1
were obtained from the I.M.A.G.E. consortium (47).
The PRMT6 and PRMT1 cDNA clones were sequenced
and the cDNAs were cloned into a pCMX or pCM5-based
expression vectors. The PRMT6 mutant containing the
open reading frame of PRMT6 with amino acids 86 and
88 changed from valine/aspartic acid to lysine/alanine
respectively (V86K/D88A), was produced by low-cycle
polymerase chain reaction (PCR) using pfu-turbo DNA
polymerase (Stratagene). A wild-type PRMT6 clone con-
taining only the PRMT6 open reading frame was also
produced by low-cycle PCR using pfu-turbo DNA
polymerase and cloned into pCMX-VP16-N and pCMX
or pCM5-based expression vectors. All PCR-generated
clones were veriﬁed by sequencing and were tested by
transfection and western blotting to ensure that they
generate similar expression levels as vectors expressing
wild-type proteins. The precise cloning steps for the
clones used are available on request. The RHCglo
minigene was a gift from Dr Thomas A. Cooper (48).
To make the RHCglo-SYK-Exon 7 minigene, PCR
primers targeting intron 6 (50-GCGCGTCGACGCTCG
GTGAGACAGATCCATA-30) and intron 7 (50-GCGC
GGCTAGCCTCAGATTACACCTCTTCTTTAC-30)
were used with HeLa cell genomic DNA, PfuUltra II
Fusion HS DNA polymerase and PCR to produce a
human genomic DNA fragment encompassing 602bp of
intronic sequence upstream of Syk Exon 7, and 532bp
of intronic sequence downstream of Exon 7. This
PCR product was digested with Sal1/Nhe1, agarose gel
isolated and cloned into the Sal1/Xba1 sites of the
RHCglo minigene reporter. The cloned Syk PCR
sequence was conﬁrmed by sequencing.
Cell culture and transfection
HeLa and CV-1 cells were maintained in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) at 37 C and 5% CO2.
For luciferase assays, HeLa or CV-1 cells were plated in
24-well plates and cultured for 24h in DMEM without
phenol red, supplemented with 10% charcoal-stripped
FBS before transfection. Cells were transiently transfected
at 60–70% conﬂuence by using calcium phosphate precip-
itation with 100ng reporter, 0.15–15ng individual SHR/
NR (15ng ERa,1 5 n gE R b, 12ng PR, 15ng GR, 2.5ng
RARa or 15ng PPARg unless stated otherwise), 50ng
PRMT6, 50ng PRMT6 V86K/D88A, 50ng PRMT1,
50ng CARM1, 100ng SRC-1 as indicated and 10ng
b-galactosidase expression vectors per well. An appropri-
ate amount of empty expression vector was used in assays
without cofactor and the total amount of DNA was
brought to 1mg/well using pGEM4. Post-transfection,
cells were washed with phosphate-buﬀered saline (PBS)
and maintained in DMEM without phenol red plus 10%
charcoal-stripped serum. The media was supplemented
with the appropriate ligand as indicated: 10
–8M
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–9M estradiol (E2), 10
–7M all-trans
retinoic acid (RA), 10
–8M Dexamethasone (Dex), 10
–5M
Ciglitazone (Cig) or vehicle alone (ethanol). After 24–36h
incubation, cells were harvested and cell extracts assayed
for luciferase and b-galactosidase activity on a Berthold
luminometer. Mammalian-2-hybrid assays were per-
formed in HeLa cells cultured in DMEM supplemented
with 10% FBS at 37 C and 5% CO2. Mammalian-
2-hybrid transfections were carried out using 100ng
pG5E1b-luciferase reporter, 25ng Gal4 or Gal4-SRC-1,
300ng VP16 or VP16-PRMT6 and 10ng b-galactosidase
expression vectors per well. After 24–36h incubation, cells
were harvested and cell extracts assayed for luciferase and
b-galactosidase activity. The luciferase assay and Tropix
b-galactosidase chemiluminescent assay were done
according to the manufacturer’s directions (Applied
Biosystems) and b-galactosidase activity was used as an
internal control to monitor for transfection eﬃciency.
For luciferase assays, data shown are the means and
standard deviations (SD) of results from four transfected
cultures.
Splicing assays using the RHCglo-Syk-Exon 7 minigene
were performed by transiently transfecting HeLa cells
grown to 50% conﬂuency in 6-well plates with 400ng of
RHCglo-Syk-Exon 7 reporter, 75ng of PRMT6, PRMT6
V86K/D88A, CARM1 or empty expression vector, and
pGEM4 to bring up total DNA to 1.5mg/well.
Transfections were performed by using Lipofectamine
TM
2000 (Invitrogen) as described by manufacturer’s instruc-
tions, and the cells were harvested 24h post-transfection.
RNA transcript quantiﬁcation using g-32P labelled
primers and real-time (RT)-PCR were performed as
previously described (29,33), using the RHCglo speciﬁc
primers RSV5U and RTRHC as previously described
(48) and RT-PCR without reverse transcriptase did not
produce any detectable PCR products (data not shown).
An autoradiograph of the radiolabeled RT-PCR products
from a representative experiment is shown. Six replicate
wells of cells were used for each experimental condition
and all experiments were repeated twice.
MCF-7 cells were maintained in DMEM nutrient
mixture F-12 plus 10% FBS. During experiments utilising
hormone, cells were plated and maintained in phenol
red-free DMEM nutrient mixture F-12 containing 10%
charcoal-stripped serum at 37 C and 5% CO2. To knock
down PRMT6 expression levels, MCF-7 cells were
transfected with small interfering RNA (siRNA)
oligonucleotide duplex at a ﬁnal concentration of 10nM
using RNAiMAX (Invitrogen) according to manufac-
turer’s instructions. The annealed siRNA duplex
sequences used were: PRMT6-siRNA-1, sense 50-CGGG
ACCAGCUGUACUACGTT-30 and PRMT6-siRNA-1,
anti-sense 50-CGUAGUACAGCUGGUCCCGTT-30.A
scrambled control was used as a negative control:
Control-siRNA, sense 50-CAGCGACUAAACACAUCA
ATT-30 and Control-siRNA, anti-sense 50-UUGAUGUG
UUUAGUCGCUGTT-30. After 48h post-transfection,
cells were treated for 12h with 10
–9M E2 or vehicle
control (ethanol) prior to harvesting RNA.
RNA extraction and quantitative RT–PCR
Total RNA was extracted from MCF-7 cells using Trizol
Reagent (Invitrogen), according to manufacturer’s
protocol. Total RNA for quantitative (Q)-RT-PCR was
further puriﬁed by using RNeasy RNA mini-puriﬁcation
columns with on column DNase treatment according
to manufacturer’s instructions (Qiagen). RNA was
normalized using UV spectrophotometry and agarose gel
electrophoresis. cDNA was synthesized from 600ng of
total RNA using TaqMan Reverse Transcription
Reagents, according to the manufacturer’s instructions
(Applied Biosystems). Gene expression levels were deter-
mined by Q-RT-PCR on a 7900HT Fast Real-Time PCR
System (Applied Biosystems) using Assay on Demand
Taqman primer/probes (Applied Biosystems); PRMT6
(Hs00250803_s1), CARM1/PRMT4 (Hs00406354_m1),
PRMT1 (Hs01587651_g1), GREB1 (Hs00536409_m1),
PR (Hs01556701_m1), ERa (Hs01046818_m1) and
normalised to GAPDH (Cat#4326317E) and RPLP0
(Cat#4326314E) expression levels. Target cDNA levels
were analyzed by Q-RT-PCR in 10ml reactions using
Taqman PCR master mix, Taqman probe/primer sets
and cDNA (5% of the starting 600ng of RNA). PCR
was initiated at 95 C for 10min to activate Amplitaq
Gold DNA polymerase, followed by 45 cycles of 95 C
for 15s and 60 C for a 1-min two-step thermal cycling.
Relative changes in gene expression were calculated using
the Ct method. For each experiment, four replicate
wells of cells were used for each experimental condition
and all experiments were repeated twice.
In order to determine the eﬀects of PRMT6 on splicing
of the endogenous vascular endothelial growth factor
(VEGF) nascent RNA, a modiﬁed version of the
protocol described by Wellmann et al. (49) was used. In
order to detect levels of total VEGF transcript
(VEGFtotal) and three splice products VEGF121,
VEGF165 and VEGF189, a common forward primer
(50-CCCTGATGAGATCGAGTACATCTT-30) and
common ﬂuorescent hydrolysation probe (50-ATCCTGT
GTGCCCCTGATGCGATGCGGT-30) both located on
exon 3 were used (Supplementary Figure S6A). Speciﬁc
ampliﬁcation of each spliced product was achieved by
using reverse primers spanning exon boundaries speciﬁc
for the relevant product. Reverse primers used
were: VEGF121 (50-GCCTCGGCTTGTCACATTTT-30),
VEGF165 (50-AGCAAGGCCCACAGGGATTT-30),
VEGF189 (50-AACGCTCCAGGACTTATACCG-30) and
VEGFtotal (50-ACCGCCTCGGCTTGTCAC-30). Expres-
sion levels were normalized to GAPDH and RPLP0, and
changes in the expression of the spliced variants was
normalized to VEGFtotal. Relative changes in gene expres-
sion were calculated using the Ct method. Four
replicate wells of cells were used for each experimental
condition and all experiments were repeated twice.
Alterations in the splicing of spleen tyrosine kinase
(Syk) were detected using a modiﬁed protocol described
by Wang et al. (50). The primers used to amplify Syk
(Syk[L]) and the shorter alternatively spliced isoform
(Syk[S]) were Syk-for 50-AATCGGCACACAGGGAAA
TG-30 and Syk-rev 50-AGCTTTCGGTCCAGGTAA
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50-GATGAGTATGCCTGCCGTGTG-30 and b2-rev
50-CAATCCAAATGCGGCATCT-30. The primers were
radiolabelled using
32P-gATP (3000Ci/mmol) and T4
kinase (Invitrogen). To amplify the Syk and
b2-microglobulin cDNA, PCR was conducted for 30
cycles (30s at 94 C, 45s at 56 C and 1min at 68 C) and
radioactive PCR products were separated on
non-denaturing 5% polyacrylamide gels. Dried gels were
subject to autoradiography and phosphorimaging using a
Storm 860 phosphorimager and ImageQuant software
(Molecular Dynamics). Levels of Syk alternatively
spliced products were normalized to b2-microglobulin
expression levels. An autoradiograph of the radiolabelled
PCR products from a representative experiment is shown.
Four replicate wells of cells were used for each experimen-
tal condition and all experiments were repeated twice.
DNA products from the alternative splicing experiments
were sub-cloned into pCR2.1 using the TOPO-TA cloning
kit (Invitrogen) and DNA sequences conﬁrmed by DNA
sequencing on a 3730xl DNA Analyzer (Applied
Biosystems).
Cell proliferation assays
Cell proliferation assays were performed in 96-well plates
in phenol red-free DMEM nutrient mixture F-12 contain-
ing 10% charcoal-stripped serum. siRNA was transfected
into MCF-7 cells (10000 cells/well) using RNAiMAX
(Invitrogen) according to manufacturer’s instructions.
Cells were transfected either with 20nM control siRNA,
10nM siRNA targeting PRMT6 and/or 10nM siRNA
targeting CARM1; CARM1-siRNA-1, sense 50-ACCAA
AUGAUGUCCCUGCCTT-30 and CARM1-siRNA-1,
anti-sense 50-GGCAGGGACAUCAUUUGGUTT-30.
When transfecting siRNA targeting either PRMT6 or
CARM1, 10nM control siRNA was added to make a
ﬁnal siRNA concentration of 20nM. After 24h, cells
were treated with 10
–9M E2 or vehicle control (ethanol).
The proliferation assay was conducted by incubating the
cells with a ﬁnal concentration of 10mCi/ml
3H-thymidine
for 19h. The cells were then lysed and incorporated
3H-thymidine was harvested onto a ﬁlter mat (Wallac).
The
3H-thymidine levels were counted using a 1450
MicroBeta TriLux scintillation counter (Wallac)
according to manufacturer’s instructions.
Western blotting
Cellular extracts (20mg) were separated by 10% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and electroblotted/transferred on to
polyvinylidene ﬂuoride membrane (Sigma–Aldrich).
Non-speciﬁc binding sites were blocked by immersing
the membranes in 5% skim milk/TBS buﬀer (20mM
Tris–HCl, pH 7.6, 137mM NaCl, 0.5% Tween 20) for
1–2h at room temperature and the membrane was
subsequently incubated with polyclonal PRMT6 (Sigma–
Aldrich), CARM1 (Bethyl Laboratories), ERa (Santa
Cruz Biotechnology) or b-tubulin (Sigma–Aldrich)
antibodies in 1% skim milk/TBS at a concentration of
1mg/ml O/N at 4 C, then washed three times in TBS
containing 0.05% Tween 20. Further steps involving
goat anti-rabbit or goat anti-mouse horseradish
peroxidase-conjugated secondary antibodies (Invitrogen)
as required and the catalysed oxidation of luminal were
carried out with Pierce ECL western blotting detection
reagents according to the manufacturer’s protocols.
Western blot images were obtained and recorded using a
CHEMI5000 chemiluminescence documentation system
and Chemi-Capt software. Densitrometry was performed
using Bio-proﬁl Bio-1D software.
In vitro binding assay and chromatin
immunoprecipitation assay
Glutathione S-transferase (GST) and GST-PRMT6 were
isolated from Escherichia coli BL21 or JM109 cells follow-
ing 5h induction with 0.1mM isopropyl thio-b-D-
galactosidase. Cells were harvested in MTPBS buﬀer
[150mM NaCl, 16mM Na2HPO4, 4mM NaH2PO4 (pH
7.3) plus protease inhibitors (Roche)], sonicated and
centrifuged at 3000g to remove cell debris. Five-hundred
nanograms of GST-fusion proteins were isolated by incu-
bation with GST beads (Amersham Biosciences) for 3h
with rotation at 4 C. Beads were washed ﬁve times in
buﬀer C [20mM HEPES (pH 7.6), 100mM KCl,
0.2mM EDTA, 20% (v/v) glycerol, 1mM DTT plus
protease inhibitors (Roche)] and resuspended in 200ml
HEMG buﬀer [100mM KCl, 40mM HEPES (pH 7.5),
0.2mM EDTA, 0.1% NP-40 and 10% glycerol] plus
5%w/v glycine and 0.4mg/ml BSA.
35S-methione
labelled proteins were synthesized using TNT Quick
Coupled Transcription/Translation System (Promega).
In vitro binding assays were performed by incubating
10–20ml
35S-methione labelled protein with GST-protein
bound beads for 16h at 4 C with rotation. Beads were
then washed three times with HEMG buﬀer plus 5%w/v
glycine and 0.4mg/ml BSA and then twice in HEMG
buﬀer alone. Proteins were eluted from the beads with
Laemmli sample buﬀer and analysed by SDS-PAGE and
autoradiography. All experiments were repeated twice.
Chromatin immunoprecipitation (ChIP) was performed
as previously described (51), using the MCF-7 breast
cancer cell line and anti-PRMT6 monoclonal antibody
(Sigma–Aldrich). To analyse the levels of recruitment of
PRMT6 to the endogenous GREB1 and PR genes,
immunoprecipitated chromatin was quantiﬁed by
SYBR-green RT-PCR using previously described primer
sequences (52–54).
Statistical analysis
Statistical analysis was performed using either one-
or two-tailed Student’s t-tests as appropriate.
RESULTS
PRMT6 enhances steroid-hormone-dependent
transcription
PRMT6 is a nuclear protein that is related to the
SHR/NR coactivators PRMT1 and CARM1 (55). We
therefore investigated whether PRMT6 can enhance the
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assays in mammalian cells (Supplementary Figure 1 and
Figure 1). HeLa cells were transfected with a SHR/NR
expression vector, an appropriate luciferase reporter
and an expression vector for PRMT6 as indicated. As
shown in Figure 1A, PRMT6 signiﬁcantly increased the
activity of ERa on an ERE-E1b-luciferase reporter in
a ligand-dependent manner by  1.5-fold. In a similar
experiment investigating the activity of ERb, PRMT6
increased transcriptional activity by  2.1-fold (Figure
1B). Furthermore, PRMT6 enhanced the transcriptional
activity of the progesterone receptor (PR) by  3.7-fold
and the glucocorticoid receptor (GR) by  1.7-fold
(Figures 1C and D). Similar results were also obtained
in CV-1 cells (Supplementary Figure S1A–D). All
increases in transcriptional activity were ligand-
dependent, showing that PRMT6 acts as a coactivator
for SHRs rather than a general transcription enhancer.
In contrast, PRMT6 was unable to coactivate several
non-steroidal NRs tested, including the RARa, PPARg
and TRb (Figure 1E and F, and data not shown). These
NRs were still responsive to other known coactivators,
demonstrating that the reporter had not reached its
maximal level in the presence of ligand-bound receptor
(Supplementary Figure S2). Therefore, transcriptional
coactivation stimulated by PRMT6 has speciﬁcity in
relation to certain SHR/NRs.
PRMT6 requires its enzymatic activity to function as
a coactivator
In order to determine the importance of arginine methyla-
tion on the ability of PRMT6 to function as a trans-
criptional coactivator, we engineered a previously
described PRMT6 methylation-deﬁcient mutant (VLD/
KLA at amino acids 86/88) (43). In HeLa and CV-1
cells, the PRMT6 V86K/D88A mutant was unable to
function as a coactivator for SHRs/NRs and did not
coactivate ERa,E R b, PR or GR (Figure 1A–D and
Supplementary Figure S1A–D). In both HeLa and CV-1
cells, the PRMT6 V86K/D88A mutant functioned in a
dominant-negative fashion by decreasing the transcrip-
tional activity of the PR to lower than observed with the
receptor alone. From these experiments, we determined
that PRMT6 requires its enzymatic activity to function
as a transcriptional coactivator for SHRs.
Mechanism of recruitment of PRMT6 to SHRs
PRMT1 and CARM1 have both been shown to be sec-
ondary coactivators that are recruited to SHRs/NRs via
the AD2 domains of p160/SRC proteins. It has been
demonstrated that this leads to a synergistic response in
transcriptional activation when either PRMT1 and
CARM1 is co-transfected with a member of the p160/
SRC family (12,13). In order to determine whether
PRMT6 is also a secondary coactivator, we investigated
the transcriptional response of ERa on an ERE-E1b-
luciferase reporter in the presence of both PRMT6 and
SRC-1 in CV-1 cells (Figure 2A). For this experiment,
we reduced the levels of ERa to 5ng as synergy between
multiple PRMTs and p160/SRC proteins has been
demonstrated to require low levels of SHR/NRs (13).
This lower ERa level reduces the response of the
reporter to ERa and E2 alone, while allowing greater
levels of coactivation to be observed by exogenous
coactivators. At this lower ERa level, SRC-1 increased
transcriptional activity by  7.1-fold and PRMT6 by
 4.1-fold compared to the response to ERa alone.
However, SRC-1 and PRMT6 together lead to a
synergistic enhancement of transcription of  44.7-fold.
We therefore investigated the binding of PRMT6 to
SRC-1 using a mammalian-two-hybrid assay. PRMT6
was cloned into pCMX-VP16-N to produce a VP16
transcriptional activation domain/PRMT6 chimera
(VP16-PRMT6) and SRC-1 was cloned into pCMX-
GAL4-N to produce a Gal4 DNA-binding domain/
SRC-1 chimera (Gal4-SRC-1). Co-transfection of
VP16-PRMT6 and Gal4-SRC-1 lead to a signiﬁcant
increase in luciferase activity compared to transfection
of either plasmid alone, demonstrating that PRMT6 is
able to associate with full-length SRC-1 within the
context of mammalian cells (Figure 2B). This interaction
was conﬁrmed using GST-pull-down assays with
GST-tagged PRMT6 and
35S-labelled SRC-1 (Figure
2C). Luciferase, used as a negative control, showed no
interaction with PRMT6 in GST-pull-down assays. In
order to determine which regions of SRC-1 interact with
PRMT6, we divided the SRC-1 protein into three regions
(Figure 2C). An amino-terminal region of SRC-1, contain-
ing the bHLH/PAS domain and the NR boxes, weakly
interacted with PRMT6. The central region of SRC-1,
from amino acids 620–1006, containing the NR boxes
and AD1 domain, showed no interaction with PRMT6.
However, PRMT6 did bind strongly to the
carboxyl-terminal region of SRC-1 composed of amino
acids 1006–1441, which contains the AD2 domain.
We then investigated whether PRMT6 is recruited to an
active oestrogen-dependent promoter in response to
oestrogen. ERa binds to three EREs to activate transcrip-
tion of the GREB1 gene, but does not bind at a region
6kb downstream of the GREB1a transcription start site
(52). We, therefore, investigated whether PRMT6 is
recruited to these sites in response to oestrogen treatment
using ChIP assays. Following 15min oestrogen stimula-
tion, PRMT6 was recruited to EREs in the GREB1
promoter (Figure 2D). This recruitment was cyclical and
returned to baseline levels after 45min oestrogen treat-
ment. There was no recruitment of PRMT6 to the 6kb
downstream site, which served as a negative control. We
then examined PRMT6 recruitment to a second
oestrogen-dependent gene, the progesterone receptor.
ERa binds to an enhancer located +169kb downstream
of the PR transcriptional start site (53,56). ChIP assays
demonstrated that PRMT6 is recruited to this enhancer
region following 15min oestrogen stimulation (Figure
2E). Again, PRMT6 occupancy returned to baseline
levels after 45min oestrogen treatment. A region 5kb
downstream of the PR transcriptional start site, that
does not show ERa binding (54), served as a negative
control and showed no PRMT6 occupancy.
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Figure 1. PRMT6 coactivates SHRs in HeLa cells. (A) PRMT6 coactivates ERa transcriptional activity from an oestrogen response element linked
to a minimal promoter. HeLa cells were co-transfected with an ERE-E1b-luciferase reporter along with expression vectors for ERa alone, or with
PRMT6 or PRMT6 V86K/D88A as indicated. Cells were treated with vehicle (ethanol) or 10
 9M E2 as indicated and tested for luciferase activity
(see ‘Materials and Methods’ section). (B) PRMT6 coactivates ERb transcriptional activity from the ERE-E1b-luciferase reporter. HeLa cells were
co-transfected with an ERb expression plasmid as in (A). (C) PRMT6 enhances the transcriptional activity of PR. HeLa cells were co-transfected
with a PRE-E1b-luciferase reporter along with expression vectors for PR alone, or with PRMT6 or PRMT6 V86K/D88A mutant and treated with
vehicle (ethanol) or 10
 8M Pg as indicated. (D) PRMT6 enhances the transcriptional activity of GR. HeLa cells were co-transfected with
PRE-E1b-luciferase reporter along with expression vectors for GR alone, or PRMT6 or PRMT6 V86K/D88A mutant and treated with vehicle
(ethanol) or 10
 8M Dex as indicated. (E) PRMT6 does not coactivate the RARa. HeLa cells were co-transfected with RARE-E1b-luciferase reporter
along with expression vectors for RARa alone, or with PRMT6 or PRMT6 V86K/D88A mutant and treated with vehicle (ethanol) or 10
–7MR Aa s
indicated. (F) PRMT6 does not coactivate PPARg transcriptional activity. HeLa cells were co-transfected with a PPAR-TK-luciferase reporter along
with expression vectors for PPARg alone, or with PRMT6 or PRMT6 V86K/D88A mutant and treated with vehicle (ethanol) or with 10
–5M Cig as
indicated. Each data point represents the mean and standard deviation (SD) of results from four transfected cultures. Results shown are from a single
experiment, which is representative of three independent experiments. *P<0.001; NS, no signiﬁcant change.
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CARM1 in the presence of SRC-1
It has been previously demonstrated that transient
transfection experiments using very low levels of SHR
display a greater requirement for several coactivators
(13). Under these conditions, CARM1 and PRMT1 coop-
erate to synergistically enhance transcription in the
presence of a p160/SRC protein. In order to determine
whether PRMT6 is also capable of cooperating with
other PRMTs, we transfected CV-1 cells with a very low
level of ERa (0.15ng) and various combinations of
PRMT1, CARM1, PRMT6 and SRC-1 in luciferase
reporter assays (Figure 3). At this low level of SHR,
none of the PRMTs alone could stimulate transcription,
as observed in previous studies (13). This is due to the
requirement of several coactivators to stimulate transcrip-
tion at this level of SHR. However, co-transfection of
PRMTs with SRC-1 led to an increase in ERa
transcriptional activity, conﬁrming the roles of PRMTs
as secondary coactivators (Figure 3; compare lanes 5 to
2, 6 to 3 and 7 to 4). Co-transfecting combinations of two
of the PRMTs together in the absence of SRC-1 had little
eﬀect on transcriptional activation. However, PRMT1
and CARM1 cooperated to stimulate ERa activity in
the presence of SRC-1 (Figure 3, lane 12). Similar
results were obtained when PRMT6 was substituted for
PRMT1, indicating that PRMT6 acts cooperatively with
CARM1 and SRC-1 to promote ERa-dependent tran-
scription (Figure 3, lane 14). Interestingly, CARM1 was
necessary for this cooperative eﬀect, as the same stimula-
tion was not seen when SRC-1, PRMT1 and PRMT6 were
co-transfected (Figure 3, lane 13). In addition, transfecting
all three PRMTs together gave a similar transcriptional
response as transfecting CARM1 with either PRMT1 or
PRMT6 (Figure 3, lane 15). Therefore, both PRMT1 and
PRMT6 cooperate with CARM1 to stimulate
ERa-dependent transcription, but do not cooperate
together. Furthermore, this enhanced transcriptional
response is dependent on the presence of SRC-1.
PRMT6 is an integral component of the
oestrogen-signalling pathway
In order to determine the importance of PRMT6 in the
transcription of hormone-responsive genes within mam-
malian cells, we used siRNA interference to knockdown
PRMT6 in MCF-7 cells and determined the eﬀects on
transcription of endogenous oestrogen-regulated genes.
Transfection of PRMT6-siRNA-1 into MCF-7 cells
reduced PRMT6 levels by  80% at both the RNA and
protein levels (Figure 4A–C). Importantly, knockdown by
PRMT6-siRNA-1 was speciﬁc for PRMT6 and had no
eﬀect on the RNA levels of CARM1 and PRMT1, and
no eﬀect on the protein levels of CARM1 (Figure 4A, D
and E). Knockdown of PRMT6 also had no eﬀect on the
levels of ERa at either the RNA or the protein level
(Supplementary Figure S3). As PRMT6 is recruited to
the promoter and enhancer regions of the GREB1 and
PR genes (Figure 2D and E), we determined whether
PRMT6 is required for the activation of these genes.
Compared to treatment with a control siRNA,
knockdown of PRMT6 had no signiﬁcant eﬀect on the
transcription of GREB1 and PR in the absence of
oestrogen (Figure 4F and G). However, the
oestrogen-activated expression of both GREB1 and PR
was signiﬁcantly reduced by PRMT6 knockdown. This
result establishes a role for PRMT6 in the activation of
oestrogen-dependent transcription and the expression of
endogenous oestrogen-regulated genes. A second PRMT6
siRNA targeting the 30UTR of PRMT6
(PRMT6-siRNA-2) was also tested and produced similar
results (Supplementary Figure S4).
PRMT6 mediates oestrogen-dependent proliferation
As PRMT6 plays a role in oestrogen signalling, we investi-
gated whether PRMT6 is involved in the oestrogen-
stimulated proliferation of ERa-expressing breast cancer
cells. We used PRMT6-siRNA-1 to knockdown PRMT6
expression in MCF-7 cells and measured cellular prolifer-
ation following oestrogen treatment. As CARM1 is
known to play a role in MCF-7 cell proliferation in
response to oestrogen (57), we also knocked down
CARM1 expression to allow the eﬀects of these two
PRMTs to be compared. In addition, as PRMT6 and
CARM1 can function synergistically in oestrogen signal-
ling (Figure 3), we also knocked down the two proteins
together to see if they function cooperatively in regulating
oestrogen-induced proliferation. The siRNA trigger tar-
geting CARM1 reduced CARM1 expression by  80%
without aﬀecting PRMT6 or PRMT1 expression
(Supplementary Figure S5A–C). Knockdown of either
PRMT6 or CARM1 levels signiﬁcantly reduced the pro-
liferation of MCF-7 cells 72 and 96h after oestrogen treat-
ment compared to treatment with control siRNA.
Reducing the levels of either PRMT6 or CARM1
resulted in a similar inhibition of oestrogen-stimulated
proliferation (Figure 5A). In addition, treating the cells
with siRNAs targeting both PRMT6 and CARM1
together had an additive eﬀect, signiﬁcantly lowering pro-
liferation when compared to treatment with either siRNA
individually. These eﬀects were oestrogen dependent, as
knocking down PRMT6 and CARM1 either individually
or together had no eﬀect on MCF-7 proliferation in the
absence of oestrogen (Figure 5B). Similar results were also
obtained using P6-siRNA-2 (Supplementary Figure S5D
and E). Therefore, PRMT6 is an integral component of
the oestrogen-signalling pathway, and is required to stim-
ulate both oestrogen-dependent transcription and cellular
proliferation.
PRMT6 regulates alternative splicing
To investigate the ability of PRMT6 to regulate alterna-
tive splicing, we examined the splicing of the VEGF gene
following knockdown of PRMT6 in MCF-7 cells.
Alternative splicing of VEGF produces several major
spliced forms of mRNA (58). We used Q-RT-PCR
analysis to determine the relative levels of three of these
isoforms: full-length VEGF (VEGF189), VEGF following
skipping of exon 6 (VEGF165) and VEGF following
skipping of exons 6 and 7 (VEGF121) (Figure 6A).
MCF-7 cells were transfected with either control siRNA
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Figure 2. PRMT6 synergistically coactivates ERa transcriptional activity in the presence of SRC-1. (A) CV-1 cells were transiently co-transfected
with an ERE-E1b-luciferase reporter, 5-ng expression vector for ERa, along with expression vectors for PRMT6 or SRC-1 as indicated. Following
treatment with vehicle (ethanol) or 10
–9M E2, cells were assayed for luciferase activity. Numbers above bars show fold increase in luciferase activity
compared to transfection with ERa alone and 10
–9M E2 stimulation. Each data point represents the mean and SD of results from four transfected
cultures. Results shown are from a single experiment, which is representative of three independent experiments. (B) Mammalian-2-hybrid analysis
demonstrates that PRMT6 interacts with full-length SRC-1. HeLa cells were co-transfected with pG5-E1b-luciferase reporter plasmid along with
expression vectors for the Gal4 DNA-binding domain alone (Gal4), Gal4-SRC-1 chimera, the VP16 transcriptional activation domain alone (VP16)
or VP16-PRMT6 chimera as indicated. Cell extracts were tested for luciferase activity. Each data point represents the mean and SD of results from
2208 Nucleic Acids Research, 2010,Vol.38, No. 7or PRMT6-siRNA-1 and knockdown of PRMT6 was
veriﬁed by Q-RT-PCR (Supplementary Figure S6B–D).
Whilst reduction of PRMT6 transcript had no eﬀect on
levels of VEGF121, it did produce a signiﬁcant increase in
the levels of VEGF189 and a decrease in the levels of
VEGF165 compared to treatment with control siRNA
(Figure 6B). This leads to a >2-fold increase in the
VEGF189:VEGF165 ratio (Figure 6C). This change was
observed in both the presence and absence of oestrogen,
despite the transcription of VEGF being oestrogen-
regulated (Supplementary Figure S6H). Therefore, the
regulation of alternative splicing of VEGF by PRMT6
does not require steroid hormone stimulation. A similar
change in VEGF splicing was observed following PRMT6
knockdown by a diﬀerent siRNA targeting PRMT6
(PRMT6-siRNA-2) (Supplementary Figure S6E–G and
S6I-K). These results suggest that PRMT6 can play a
role in the alternative splicing of endogenous genes in
MCF-7 cells, and in contrast to its eﬀects on transcription,
the regulation of alternative splicing is hormone-
independent. As CARM1 can also regulate alternative
splicing in a steroid hormone-independent manner, we
investigated whether PRMT6 and CARM1 are redundant
for splicing of VEGF. Two siRNAs were designed to
signiﬁcantly reduce the levels of CARM1, but not
PRMT6 or PRMT1 (Supplementary Figure S7A–C).
Similar to PRMT6, knockdown of CARM1 in MCF-7
cells had no eﬀect on VEGF121 and signiﬁcantly reduced
the levels of VEGF165 (Supplementary Figure S7E).
However, in contrast to PRMT6, CARM1 knockdown
had no eﬀect on the levels of VEGF189 (Supplementary
Figure S7E). Therefore, PRMT6 and CARM1 display
similar but not redundant eﬀects on the splicing of VEGF.
To further investigate the ability of PRMT6 to regulate
RNA processing, we examined the eﬀect of PRMT6 on
the alternative splicing of Syk. Syk is expressed in breast
tissue and has been implicated to play a role in breast
cancer (59). Two alternatively spliced isoforms of Syk
have been documented (Figure 6D): full-length Syk
(Syk[L]) and a shorter form that lacks a 69-bp sequence
comprising exon 7 (Syk[S]) (60–62). In order to investigate
the regulation of alternative splicing of the endogenous
Syk gene by PRMT6, PRMT6 levels were reduced
in MCF-7 cells using PRMT6-siRNA-1. The two
diﬀerent Syk transcripts were then detected by reverse
transcriptase-PCR with
32P-radiolabelled primers that
span the alternative exon of Syk[L]. PRMT6 knockdown
led to a signiﬁcant increase in the Syk[L]:Syk[S] ratio
(Figure 6F and Supplementary Figure S8A). A similar
result was seen using a second siRNA directed against
four transfected cultures. Results shown are from a single experiment, which is representative of three independent experiments. *P<0.001. (C) GST
pull-down assays were used to test the ability of GST-PRMT6 to interact with full length or fragments of
35S-radiolabelled SRC-1. GST alone and
in vitro translated
35S-radiolabelled luciferase served as negative controls. A schematic representation of the SRC-1 protein fragments used in the
assays is shown in the panel, with amino acid positions of the SRC-1 protein or SRC-1 protein fragments indicated. The major functional domains of
SRC-1 are indicated, bHLH/PAS, NR Boxes, AD1 and AD2. (D) Recruitment of PRMT6 to oestrogen response elements (EREs) located in
promoter regions of the GREB1 gene. Following 0-, 15- and 45-min treatment of MCF-7 cells with 10
 9M E2, recruitment of PRMT6 to EREs
in the GREB1 promoter and to a site downstream of the GREB1 transcriptional start site (+6kb) was determined by chromatin immunopre-
cipitation as detailed in ‘Materials and Methods’ section. Results show the average and SD of four independent experiments. (E) Recruitment of
PRMT6 to an oestrogen-receptor-binding enhancer region of the PR gene. Following 0-, 15- and 45-min treatment of MCF-7 cells with 10
 9M E2,
recruitment of PRMT6 to a known oestrogen-receptor-binding enhancer region of the PR gene (PR ERE) and to a site downstream of the PR gene
transcriptional start site (+5kb) was determined by chromatin immunoprecipitation as detailed in ‘Materials and methods’ section. Results show the
average and SD of four independent experiments.
Figure 3. PRMT6 and CARM1 synergistically coactivate ERa transcriptional activity in the presence of SRC-1. CV-1 cells were co-transfected with
an ERE-E1b-luciferase reporter, 0.15-ng expression vector for ERa, and combinations of expression vectors for PRMT6, CARM1, PRMT1 or
SRC-1 as indicated. Following oestrogen treatment, cells were assayed for luciferase activity. Numbers above bars show fold increase in luciferase
activity upon 10
 9M E2 stimulation. Each data point represents the mean and SD of results from four transfected cultures. Results shown are from
a single experiment, which is representative of three independent experiments.
Nucleic Acids Research,2010, Vol.38, No. 7 2209PRMT6 (PRMT6-siRNA-2) (Supplementary Figure S8B).
Taqman Q-RT-PCR using primers and probes designed to
detect the alternative isoforms of Syk gave similar results
(Supplementary Figure S8C and D). As with the alterna-
tive splicing of VEGF, the eﬀects of PRMT6 on alterna-
tive splicing of Syk were hormone independent. In order
to investigate the eﬀects of CARM1 on alternative splicing
of endogenous Syk, two siRNAs were employed that spe-
ciﬁcally target CARM1 (Supplementary Figure S7A–C).
Following reduction of CARM1 levels in MCF-7 cells,
Taqman Q-RT-PCR was used to detect the endogenous
levels of the Syk isoforms. CARM1 knockdown did not
inﬂuence splicing of the endogenous Syk RNA transcripts
(Supplementary Figure S8E). Therefore, as with the
VEGF gene, PRMT6 and CARM1 are not redundant in
the splicing of Syk.
In order to verify the observed eﬀects of PRMT6 and
CARM1 on the splicing of Syk, we developed a minigene
containing the alternatively spliced exon 7 of the Syk gene
(Figure 6E). We transfected this minigene into HeLa cells
along with PRMT6, PRMT6 V86K/D88A mutant or
CARM1 and determined the levels of the Syk isoforms
by reverse transcriptase-PCR with
32P-radiolabelled
primers. Over-expression of PRMT6 signiﬁcantly
reduced the Syk Exon 7 Inclusion:Exclusion ratio to
 50% of control levels (Figure 6G). This is in agreement
with our data showing that knocking down PRMT6 leads
to an approximate 2-fold increase in the Syk[L]:Syk[S]
ratio (Figure 6F). The PRMT6 V86K/D88A mutant had
no eﬀect on the splicing of the RHCglo-Syk-Exon 7
minigene, demonstrating that PRMT6 requires its enzy-
matic activity to regulate RNA processing (Figure 6G).
In addition, CARM1 had no aﬀect on the alternative
splicing of the RHCglo-Syk-Exon 7 minigene, as
observed with the splicing of the endogenous Syk gene
(Figure 6G and Supplementary Figure S8E). This vali-
dates our ﬁndings on the regulation of the endogenous
Syk gene, and demonstrates that PRMT6 and CARM1
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Figure 4. Knockdown of PRMT6 expression disrupts oestrogen signalling. (A) Western blot showing PRMT6, CARM1 and b-tubulin expression in
MCF-7 cells following transfection with control siRNA (Ctrl-siRNA) or siRNA targeting PRMT6 (P6-siRNA-1) and treatment with or without
10
 9M E2 for 12h as indicated. (B) Graphical representation of PRMT6 expression levels of western blot shown in (A). (C) Q-RT-PCR analysis of
PRMT6 RNA levels in MCF-7 cells following transfection by control siRNA or siRNA targeting PRMT6 and treatment with or without 10
 9ME 2
for 12h as indicated. (D) CARM1 expression as detected in (C). (E) PRMT1 expression as detected in (C). (F) GREB1 expression levels following
PRMT6 knockdown. RNA was analysed by Q-RT-PCR for expression of GREB1 as in (C). (G) PR expression levels following PRMT6 knockdown.
PR levels were examined as in (C). Each data point represents the mean and SD of results from four transfected cultures. Results shown are from
a single experiment, which is representative of two independent experiments. *P<0.005; NS, no signiﬁcant change compared to treatment with
control siRNA.
2210 Nucleic Acids Research, 2010,Vol.38, No. 7regulate the alternative splicing of a diﬀerent subset
of genes.
DISCUSSION
Coupling of RNA polymerase-II-mediated transcription
and RNA processing is a well-established concept (63).
These two processes can be functionally linked by the
activity of SHR/NR coactivators. This was ﬁrst
demonstrated by the PPARg coactivator PGC-1, which
can regulate alternative splicing of the ﬁbronectin
minigene (64). Further investigations have demonstrated
that other coactivators, including CoAA, p72, Sam68,
p68, ASC-1 and ASC-2, can play this dual role, whilst
the CAPER a and b proteins have been shown to
regulate both transcription and alternative splicing in a
SHR-dependent manner (29,30,34,65). Recently,
CARM1, a PRMT known to function as a SHR/NR
coactivator, has been shown to inﬂuence alternative
splicing (31). Here, we report that another PRMT
protein, PRMT6, is a SHR/NR coactivator that can
regulate both hormone-dependent transcription and
hormone-independent alternative splicing.
We have demonstrated that PRMT6 can function as a
coactivator for ERa,E R b, PR and GR (Figure 1 and
Supplementary Figure S1). Similar to PRMT1 and
CARM1, we also demonstrate that PRMT6 requires its
enzymatic activity to function as a coactivator (Figure 1
and Supplementary Figure S1). We have further
characterized the involvement of PRMT6 on the expres-
sion of two oestrogen-stimulated genes, GREB1 and PR.
PRMT6 is cyclically recruited to the promoter and
enhancer regions of these genes in response to oestrogen
(Figure 2D and E). The recruitment of PRMT6 was
detected at these sites following 15min oestrogen treat-
ment, but had returned to baseline levels after 45min.
PRMT6 is also required to fully activate these genes, as
knockdown of PRMT6 leads to a decrease in their
oestrogen-stimulated transcription (Figure 4). This dem-
onstrates that PRMT6 is an integral component of the
oestrogen-signalling pathway and is required to fully
activate hormone-dependent transcription.
Even though PRMT6 can coactivate SHRs in the
absence of other exogenous coactivators, the mode of
action of PRMT6 is similar to that of PRMT1 and
CARM1, in that it functions as a secondary coactivator
to p160/SRC proteins. PRMT6 binds to the AD2 domain
of SRC-1, and functions synergistically with SRC-1 to
coactivate ERa (Figure 2A–C). Therefore, PRMT6 can
be added to the list of SHR coactivators that are able to
interact with SRC-1 to enhance transcriptional activation.
Two PRMTs previously identiﬁed to interact with the
p160/SRC proteins, PRMT1 and CARM1, also function
synergistically to coactivate SHRs in luciferase reporter
experiments (13). In order to determine whether PRMT6
also acts in concert with these PRMTs to stimulate gene
expression, we transfected combinations of PRMT6,
PRMT1, CARM1 and SRC-1 into CV-1 cells. We found
that PRMT6 acts synergistically with CARM1 but not
PRMT1, and synergy was dependent on the presence of
SRC-1 (Figure 3). PRMT6 and PRMT1 share
methylation targets, and so it is possible that methylation
of a common target by either PRMT6 or PRMT1 could be
required for CARM1 to further activate transcription.
However, PRMT6 and PRMT1 are not redundant in
stimulating hormone-induced gene activation, as siRNA
knockdown of PRMT6 alone leads to a signiﬁcant
decrease in oestrogen-induced GREB1 and PR expression
(Figure 4).
Potential methylation targets that may be responsible
for PRMT6 coactivation include H4R3, a target that is
shared with PRMT1 and is methylated as an early step in
oestrogen-induced gene activation (40,66,67). Other
targets include the high-mobility group (HMG) A1
proteins HMGA1a and HMGA1b (68–70). These
non-histone chromosomal proteins are involved in
chromatin structure organization and gene transcription,
although the eﬀect of arginine methylation on these
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Figure 5. Knockdown of PRMT6 and CARM1 expression inhibits
oestrogen-stimulated proliferation of breast cancer cells. (A) MCF-7
cells were transfected with control siRNA (Ctrl-siRNA) or siRNA tar-
geting PRMT6 (P6-siRNA-1), CARM1 (C1-siRNA-1) or both PRMT6
and CARM1 (P6-siRNA-1 and C1-siRNA-1). Following treatment
with 10
 9M E2, cell proliferation was determined by
3H-thymidine
incorporation. (B) MCF-7 cells were transfected as in (A) and cell
proliferation was determined by
3H-thymidine incorporation in the
absence of 10
 9M E2. Each data point represents the mean and SD
of results from eight individual cultures. Results are shown from a
single experiment, which is representative of two independent experi-
ments. *P<0.001.
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Figure 6. PRMT6 regulates alternative splicing of endogenous VEGF and Syk. (A) Schematic representation of the major spliced products of the
VEGF gene (not to scale). (B) Eﬀect of PRMT6 knockdown on alternative splicing of VEGF. MCF-7 cells were transfected either with control
siRNA (Ctrl-siRNA) or siRNA targeting PRMT6 (P6-siRNA-1) and treated either with or without 10
 9M E2 for 12h as indicated. RNA was
harvested from the cells and the relative expression level of each spliced isoform was determined by Q-RT-PCR analysis as detailed in ‘Materials and
Methods’ section. (C) The relative VEGF 189:VEGF 165 ratio was obtained by dividing the relative VEGF 189 cDNA level by the relative VEGF
165 cDNA level for each experimental condition. (D) Schematic representation of the major alternatively spliced products of the endogenous Syk
gene (not to scale). (E) Representation of the RHCglo-Syk-Exon 7 minigene construct, not to scale. (F) Eﬀect of PRMT6 knockdown on splicing of
endogenous Syk. MCF-7 cells were transfected either with control siRNA (Ctrl-siRNA) or siRNA targeting PRMT6 (P6-siRNA-1) and treated either
with or without 10
–9M E2 for 12h as indicated. RNA was harvested from the cells and Syk splicing was determined by reverse transcriptase-PCR.
The relative Syk[L]:Syk[S] ratio was obtained by dividing the relative Syk[L] cDNA level by the relative Syk[S] cDNA level for each experimental
2212 Nucleic Acids Research, 2010,Vol.38, No. 7proteins is not currently known. Another PRMT6
methylation target is H3R2, which has been reported to
be a repressive histone mark (40–42); however, in certain
conditions both of the known coactivators PRMT1 and
CARM1 can methylate this histone residue (16,17,41,71).
H3R2 methylation has been shown to prevent transcrip-
tion primarily by preventing the mixed lineage leukaemia
(MLL) K4 methyltransferase unit binding to and
methylating H3K4 (40,42). However, this mechanism
only represses a deﬁned subset of genes that are regulated
by the MLL complex (40). It is known that transcription
of oestrogen-regulated genes can occur independently of
MLL1, as siRNA targeting MLL1 has little eﬀect on tran-
scription of the prototypical oestrogen-regulated gene pS2
(72). Further evidence that H3K4 methylation is not
required for steroid hormone-activated transcription is
provided by the fact that the H3K4 demethylase LSD1
is recruited to the GREB1 enhancer site and is required
for oestrogen-dependent GREB1 transcription (72).
Indeed, 58% of ERa-enriched promoters examined by
Garcia-Bassets et al. (72) showed recruitment of LSD1,
and both glucocorticoid and DHT stimulation lead to a
decrease in dimethylation of H3K4 on a tandem array of
the mouse mammary tumour virus promoter and on the
PSA promoter respectively (17,73). Therefore, in the case
of steroid-hormone-induced gene expression it appears
that H3K4 demethylation does not prevent, and may
even promote transcription. One example of H3K4
demethylation being an activating histone mark has been
provided by the autoimmune regulator, which binds to
non-methylated H3K4 and promotes transcription (74).
Further studies will have to be conducted to determine
the complete role of H3R2 and H3K4 methylation in
steroid-hormone-activated transcription.
As PRMT6 can regulate oestrogen-dependent transcrip-
tion; we investigated whether it is also involved in the
oestrogen-stimulated proliferation of ER+breast cancer
cells. Reducing PRMT6 levels by siRNA interference
signiﬁcantly inhibited the oestrogen-dependent, but not
oestrogen-independent, proliferation of MCF-7 cells
(Figure 5). This demonstrates that PRMT6 is a fundamen-
tal component of the oestrogen-signalling pathway in
breast cancer cells. This inhibition of proliferation was
similar to that obtained by knocking down CARM1,
which has previously been demonstrated to inhibit the
oestrogen-stimulated proliferation of MCF-7 cells (57)
(Figure 5). As PRMT6 and CARM1 can cooperate to
stimulate ERa-dependent transcription (Figure 3), we
investigated the eﬀects of knocking down both PRMTs
simultaneously on oestrogen-dependent proliferation.
Reducing the levels of both PRMT6 and CARM1
together further reduced oestrogen-driven MCF-7 cell
proliferation when compared to knocking down either
PRMT alone. Therefore, both PRMT6 and CARM1 are
required to stimulate oestrogen-dependent proliferation of
breast cancer cells, and their roles are not redundant in
this process.
As well as regulating transcriptional initiation, we have
shown that PRMT6 can also aﬀect aspects of RNA pro-
cessing, speciﬁcally alternative splicing. The siRNA
knockdown of PRMT6 altered the relative levels of
alternatively spliced products of the endogenous VEGF
and Syk genes (Figure 6). In both cases, PRMT6 knock-
down leads to an increase in exon inclusion, and a
decrease in exon skipping. Therefore, it would appear
that one cellular function of PRMT6 is to increase
skipping of alternative exons. The eﬀects of PRMT6 on
alternative splicing of both VEGF and Syk were steroid
hormone independent, despite the transcription of VEGF
being oestrogen-dependent (Supplementary Figure S6H).
CARM1, the only other PRMT identiﬁed to have a direct
role in alternative splicing, also regulates alternative
splicing in a hormone-independent manner (31). Unlike
several coactivators involved in coupling transcription
and alternative splicing, such as PGC-1, CoAA and
CAPERa/b, both PRMT6 and CARM1 have none of
the domains characteristic of splicing factors such as
RNA-recognition motifs and serine-arginine-rich
domains. As PRMT6 requires its enzymatic activity to
regulate the splicing of Syk (Figure 6G), the most likely
method by which it regulates alternative splicing is by
methylating other splicing proteins. In the study by
Cheng et al. (31), CARM1 and PRMT6 were found
to have diﬀerent substrate speciﬁcities in relation to
the methylation of various splicing-related proteins.
Therefore, we investigated whether PRMT6 and
CARM1 have non-redundant roles in the regulation of
alternative splicing. Both PRMTs regulate the production
of the VEGF165 isoform. However, only PRMT6 regulates
the production of the VEGF189 alternatively spliced
product (Figure 6B and Supplementary Figure S7E). In
addition, CARM1 has no eﬀect on the splicing of the Syk
gene (Figures 6G and Supplementary Figure S8E).
Therefore, CARM1 and PRMT6 play a similar yet
non-redundant role in the regulation of alternative
splicing. In conclusion, this study provides evidence that
PRMT6 has a pleiotropic role in multiple aspects of gene
expression, and is able to couple transcription and alter-
native splicing.
condition. An autoradiograph of the radiolabeled Syk and b-2-microglobulin reverse transcriptase-PCR products from a representative experiment is
shown. Lane 1; radiolabelled 100-bp DNA marker; lane 2; Ctrl-siRNA without 10
 9M E2; lane 3; Ctrl-siRNA with 10
 9M E2, lane 4; P6-siRNA-1
without 10
 9M E2; lane 5; P6-siRNA-1 with 10
 9M E2. (G) Eﬀect of PRMT6 on the splicing of an RHCglo-Syk-Exon 7 minigene. HeLa cells were
transiently co-transfected with a RHCglo-Syk-Exon 7 minigene along with expression vectors for PRMT6, the PRMT6 V86K/D88A mutant or
CARM1. RNA was harvested from the cells and Syk splicing determined by reversetranscriptase-PCR. The relative RHCglo-Syk-Exon 7 inclusion
(Syk[I]): RHCglo-Syk-Exon 7 exclusion (Syk[E]) ratio was obtained by dividing the relative Syk[I] cDNA level by the relative Syk[E] cDNA level for
each experimental condition. RT-PCR without reverse transcriptase did not produce any detectable PCR products (data not shown). A representative
autoradiograph of the radiolabelled RHCglo-Syk-Exon 7 minigene products is shown. For all experiments, each data point represents the mean and
SD of results from four transfected cultures (or six transfected cultures for the RHCglo-Syk-Exon 7 minigene experiment). Results shown are from a
single experiment, which is representative of two independent experiments. *P<0.005, #P<0.05.
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